IL3RA

Synonyms

Interleukin-3 Receptor Subunit Alpha, Interleukin-3 Receptor alpha Subunit, IL3RY, IL3RX, IL-3R Subunit Alpha, CD123 Antigen, IL-3RA, IL-3 Receptor Alpha SP2 Isoform, Interleukin 3 Receptor Subunit Alpha, IL3RAY, IL3R, IL-3 Receptor Subunit Alpha, HIL-3Ra, Interleukin 3 Receptor, Alpha (Low Affinity), CD123, IL3RA, IL-3R-Alpha,

Description

Interleukin 3 receptor alpha (low affinity) (IL3RA) is also known as CD123 (Cluster of Differentiation 123). This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. IL3RA is playing an important role in the development of leukemia and in the proliferation, differentiation and apoptosis of the leukemic cells.

KO Status

F0

Drug Information

Launched drugs: 19
Drug in clinical trials: 1
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Tagraxofusp-erzs

DTIL-3, SL-401, DT388 IL3

Approved

Texas A&M University Development Foundation

Blastic Plasmacytoid Dendritic Cell Neoplasm

HY-007

HY-007

Preclinical

Heyuan Biotechnology (Tianjin) Co Ltd

Leukemia, Myeloid, Acute

APVO-437

APVO-437

Preclinical

Aptevo

Precursor Cell Lymphoblastic Leukemia-Lymphoma

CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University)

Phase 3 Clinical

Fujian Medical University

Leukemia, Myeloid, Acute

Talacotuzumab

CSL-362, JNJ-473, CSL-362-AML, JNJ-56022473, IL-13 MAb-CSL

Phase 3 Clinical

Csl

Myelodysplastic Syndromes, Lupus Erythematosus, Systemic, Leukemia, Myeloid, Acute

CD123 CAR-T cell therapy

Phase 2 Clinical

Chongqing Precision Biotechnology Co Ltd

Leukemia, Myeloid, Leukemia, Leukemia, Myeloid, Acute

Flotetuzumab

MGD-006, S-80880

Phase 2 Clinical

Macrogenics

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Anti-CD123 chimeric antigen receptor T cell therapy (Chongqing Precision Biotech)

Phase 2 Clinical

Chongqing Precision Biotechnology Co Ltd

Leukemia, Myeloid, Acute

IMGN-632

IMGN-632

Phase 2 Clinical

Immunogen

Myeloproliferative Disorders, Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute

Anti-CD123 CAR T-cell therapy (Southwest Hospital)

Phase 2 Clinical

Southwest Hospital Chongqing

Leukemia, Myeloid

MB-102 (Mustang Bio)

MB-102

Phase 2 Clinical

Mustang Bio, City Of Hope National Medical Center

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

JNJ-63709178

JNJ-9178, CNTO-9958, JNJ-63709178

Phase 1 Clinical

Janssen Global Services Llc, Genmab

Leukemia, Myeloid, Acute

Vibecotamab

XmAb-14045

Phase 1 Clinical

Xencor

Hematologic Neoplasms, Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute

Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis)

Phase 1 Clinical

Novartis Pharma Ag, University Of Pennsylvania

Leukemia, Myeloid, Acute

Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech)

Phase 1 Clinical

Nanjing Legend Biotechnology Co Ltd

Leukemia, Myeloid, Acute

KHK-2823

KHK-2823

Phase 1 Clinical

Kyowa Hakko Kirin

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

APVO436

APVO-436

Phase 1 Clinical

Aptevo

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

UniCAR-T-CD-123

UniCAR-T-CD123

Phase 1 Clinical

Gemoab Monoclonals Gmbh

Blastic Plasmacytoid Dendritic Cell Neoplasm, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute

CD123 CAR-T cells (Hebei Senlang Biotechnology)

Phase 1 Clinical

Hebei Senlang Biological Technology Co Ltd

Leukemia, Myeloid, Acute

CSL-360

IL-3Rα, CSL-360

Phase 1 Clinical

Csl Ltd

Leukemia, Myeloid, Acute

What's Next for KO Library?

Please stay tuned for the latest progress of KO Library. We are open to co-development programs of antibody therapeutics using our RenMab™-target-knockout mice.
Please contact our team if you are interested in learning more about KO Library or partnering opportunities.